Suginami H, Kuroda G, Yano K, Kitagawa H, Matsuura S
Department of Obstetrics and Gynecology, Ehime University School of Medicine, Japan.
Endocrinol Jpn. 1988 Feb;35(1):47-55. doi: 10.1507/endocrj1954.35.47.
Twenty-six anovulatory women of polycystic ovarian (PCO)-type were treated with bromocriptine (Br) at a daily dose of 5 mg for 2 months. Ovulatory cycles were resumed in 18 (69.2%) women (Br-responders). No difference between pretreatment serum levels of FSH, LH, PRL and estradiol and FSH/LH ratios in Br-responders and nonresponders was observed. The geometric mean of circulating androstenedione (A-dione) in Br-responders (2.58 ng/ml) appeared higher than that in nonresponders (2.11 ng/ml) but was not statistically significant. The geometric mean of dehydroepiandtrosterone sulfate (DHEA-S) in Br-responders (1652 ng/ml) was lower (p less than 0.01) than that in nonresponders (2582 ng/ml). The ratio of DHEA-S to A-dione (D/A ratio) exhibited a highly significant between-group difference (p less than 0.001) (646 and 1222 for Br-responders and nonresponders, respectively). Br-nonresponders with high DHEA-S levels and D/A ratios tended to hyperproduction of adrenal androgen, and Br-responders with high A-dione levels and low D/A ratios to hyperproduction of ovarian androgen. The present study indicates that Br is effective in PCO-type women presumably with ovarian androgen hyperproduction. The efficacy of Br, when applied to PCO-type women, could be predicted with their D/A ratios.
26名多囊卵巢（PCO）型无排卵女性接受了每日剂量5毫克的溴隐亭治疗，为期2个月。18名（69.2%）女性恢复了排卵周期（溴隐亭反应者）。溴隐亭反应者与无反应者在治疗前血清促卵泡生成素（FSH）、促黄体生成素（LH）、催乳素（PRL）和雌二醇水平以及FSH/LH比值方面未观察到差异。溴隐亭反应者循环中雄烯二酮（A-二酮）的几何平均值（2.58纳克/毫升）似乎高于无反应者（2.11纳克/毫升），但无统计学意义。溴隐亭反应者硫酸脱氢表雄酮（DHEA-S）的几何平均值（1652纳克/毫升）低于无反应者（2582纳克/毫升）（p<0.01）。DHEA-S与A-二酮的比值（D/A比值）在组间表现出高度显著差异（p<0.001）（溴隐亭反应者和无反应者分别为646和1222）。DHEA-S水平和D/A比值高的溴隐亭无反应者往往肾上腺雄激素分泌过多，而A-二酮水平高且D/A比值低的溴隐亭反应者往往卵巢雄激素分泌过多。本研究表明，溴隐亭对可能存在卵巢雄激素分泌过多的PCO型女性有效。应用于PCO型女性时，溴隐亭的疗效可以用其D/A比值来预测。
